Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Sainz, Bruno ^a,b   Carron, Emily ^c   Vallespinós, Mireia ^a,b   Machado, Heather L ^c  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EMACTUZUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSCRIPTION FACTOR SOX; TUMOR NECROSIS FACTOR ALPHA;

ADULT STEM CELL; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL INFILTRATION; CELL INTERACTION; CELL SELF-RENEWAL; CELL SURVIVAL; CHRONIC INFLAMMATION; DISEASE COURSE; DISTANT METASTASIS; HUMAN; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MONOCYTE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PRECANCER; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STEM CELL NICHE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; MACROPHAGE; METABOLISM; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MACROPHAGES; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84959530818     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/9012369     Document Type: Review

References (166)

1. A. Kreso and J. E. Dick, "Evolution of the cancer stem cell model," Cell Stem Cell, vol. 14, no. 3, pp. 275-291, 2014.
2. R. Virchow, "An address on the value of pathological experiments," The BritishMedical Journal, vol. 2, no. 1075, pp. 198-203, 1881.
3. T. Lapidot, C. Sirard, J. Vormoor et al., "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice," Nature, vol. 367, no. 6464, pp. 645-648, 1994.
4. C. Li, D. G. Heidt, P. Dalerba et al., "Identification of pancreatic cancer stem cells," Cancer Research, vol. 67, no. 3, pp. 1030-1037, 2007.
5. P. C. Hermann, S. L. Huber, T. Herrler et al., "Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer," Cell Stem Cell, vol. 1, no. 3, pp. 313-323, 2007.
6. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, "Prospective identification of tumorigenic breast cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983-3988, 2003.
7. A. Eramo, L. Ricci-Vitiani, A. Zeuner et al., "Chemotherapy resistance of glioblastoma stem cells," Cell Death & Differentiation, vol. 13, no. 7, pp. 1238-1241, 2006.
8. I. Miranda-Lorenzo, J. Dorado, E. Lonardo et al., "Intracellular autofluorescence: a biomarker for epithelial cancer stem cells," Nature Methods, vol. 11, no. 11, pp. 1161-1169, 2014.
9. M. E. Prince, R. Sivanandan, A. Kaczorowski et al., "Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 973-978, 2007.
10. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, "A human colon cancer cell capable of initiating tumour growth in immunodeficient mice," Nature, vol. 445, no. 7123, pp. 106-110, 2007.
11. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., "Identification and expansion of human colon-cancer-initiating cells," Nature, vol. 445, no. 7123, pp. 111-115, 2007.
12. L. Patrawala, T. Calhoun, R. Schneider-Broussard et al., "Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells," Oncogene, vol. 25, no. 12, pp. 1696-1708, 2006.
13. T. Schatton, G. F. Murphy, N. Y. Frank et al., "Identification of cells initiating human melanomas," Nature, vol. 451, no. 7176, pp. 345-349, 2008.
14. E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M. Johnson, and S. J. Morrison, "Efficient tumour formation by single human melanoma cells," Nature, vol. 456, no. 7222, pp. 593-598, 2008.
15. S. K. Singh, C. Hawkins, I. D. Clarke et al., "Identification of human brain tumour initiating cells," Nature, vol. 432, no. 7015, pp. 396-401, 2004.
16. L. V. Nguyen, R. Vanner, P. Dirks, and C. J. Eaves, "Cancer stem cells: an evolving concept," Nature Reviews Cancer, vol. 12, no. 2, pp. 133-143, 2012.
17. K. Ishizawa, Z. A. Rasheed, R. Karisch et al., "Tumor-initiating cells are rare in many human tumors," Cell Stem Cell, vol. 7, no. 3, pp. 279-282, 2010.
18. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, "Stem cells, cancer, and cancer stem cells," Nature, vol. 414, no. 6859, pp. 105-111, 2001.
19. A. Merlos-Suárez, F. M. Barriga, P. Jung et al., "The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse," Cell Stem Cell, vol. 8, no. 5, pp. 511-524, 2011.
20. S. Pece, D. Tosoni, S. Confalonieri et al., "Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content," Cell, vol. 140, no. 1, pp. 62-73, 2010.
21. M. Todaro, M. G. Francipane, J. P. Medema, and G. Stassi, "Colon cancer stem cells: promise of targeted therapy," Gastroenterology, vol. 138, no. 6, pp. 2151-2162, 2010.
22. J.H. Bae, S.H. Park, J. H. Yang, K. Yang, and J.M. Yi, "Stemcelllike gene expression signature identified in ionizing radiationtreated cancer cells," Gene, vol. 572, no. 2, pp. 285-291, 2015.
23. A. Kreso, C. A. O'Brien, P. van Galen et al., "Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer," Science, vol. 339, no. 6119, pp. 543-548, 2013.
24. S. Dingwall, J. B. Lee, B. Guezguez et al., "Neoplastic human embryonic stem cells as a model of radiation resistance of human cancer stem cells," Oncotarget, vol. 6, no. 26, pp. 22258-22269, 2015.
25. M. C. Santos, P. B. Silva, C. O. Rodini et al., "Embryonic stem cell-related protein L1TD1 is required for cell viability, neurosphere formation, and chemoresistance in medulloblastoma," Stem Cells and Development, vol. 24, no. 22, pp. 2700-2708, 2015.
26. L. E. Santaliz-Ruiz IV, X. Xie, M. Old, T. N. Teknos, and Q. Pan, "Emerging role of nanog in tumorigenesis and cancer stem cells," International Journal of Cancer, vol. 135, no. 12, pp. 2741-2748, 2014.
27. Y.-C. Hsu and E. Fuchs, "A family business: stem cell progeny join the niche to regulate homeostasis," Nature Reviews Molecular Cell Biology, vol. 13, no. 2, pp. 103-114, 2012.
28. V. Plaks, N. Kong, Z. Werb, and V. Plaks, "The cancer stem cell niche: howessential is the niche in regulating stemness of tumor cells?" Cell Stem Cell, vol. 16, no. 3, pp. 225-238, 2015.
29. M. Hidalgo, "New insights into pancreatic cancer biology," Annals of Oncology, vol. 23, supplement 10, pp. x135-x138, 2012.
30. D. Hanahan and L. M. Coussens, "Accessories to the crime: functions of cells recruited to the tumor microenvironment," Cancer Cell, vol. 21, no. 3, pp. 309-322, 2012.
31. H. Korkaya, S. Liu, and M. S. Wicha, "Breast cancer stem cells, cytokine networks, and the tumor microenvironment," The Journal of Clinical Investigation, vol. 121, no. 10, pp. 3804-3809, 2011.
32. D. G. DeNardo, D. J. Brennan, E. Rexhepaj et al., "Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy," Cancer Discovery, vol. 1, no. 1, pp. 54-67, 2011.
33. E. Lonardo, J. Frias-Aldeguer, P. C. Hermann, and C. Heeschen, "Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness," Cell Cycle, vol. 11, no. 7, pp. 1282-1290, 2012.
34. J. W. Pollard, "Trophic macrophages in development and disease," Nature Reviews Immunology, vol. 9, no. 4, pp. 259-270, 2009.
35. E. Fessler, F. E. Dijkgraaf, F. De Sousa E Melo, and J. P. Medema, "Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?" Cancer Letters, vol. 341, no. 1, pp. 97-104, 2013.
36. E. Lonardo, P. C. Hermann, M.-T. Mueller et al., "Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy," Cell Stem Cell, vol. 9, no. 5, pp. 433-446, 2011.
37. S. Liu, C. Ginestier, S. J. Ou et al., "Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks," Cancer Research, vol. 71, no. 2, pp. 614-624, 2011.
38. H.-J. Li, F. Reinhardt, H. R. Herschman, and R. A. Weinberg, "Cancer-stimulatedmesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling," Cancer Discovery, vol. 2, no. 9, pp. 840-855, 2012.
39. I. Malanchi, A. Santamaria-Martínez, E. Susanto et al., "Interactions between cancer stem cells and their niche govern metastatic colonization," Nature, vol. 481, no. 7379, pp. 85-89, 2012.
40. G. Yu, Y. Jing, X. Kou et al., "Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma," PLoS ONE, vol. 8, no. 9, Article ID e73312, 2013.
41. S. M. Cabarcas, L. A. Mathews, and W. L. Farrar, "The cancer stem cell niche-there goes the neighborhood?" International Journal of Cancer, vol. 129, no. 10, pp. 2315-2327, 2011.
42. R. Noy and J.W. Pollard, "Tumor-associatedmacrophages: from mechanisms to therapy," Immunity, vol. 41, no. 1, pp.49-61, 2014.
43. L. Bingle, N. J. Brown, and C. E. Lewis, "The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies," Journal of Pathology, vol. 196, no. 3, pp. 254-265, 2002.
44. B.-Z. Qian and J. W. Pollard, "Macrophage diversity enhances tumor progression and metastasis," Cell, vol. 141, no. 1, pp. 39-51, 2010.
45. R. M. Steinman and J. Idoyaga, "Features of the dendritic cell lineage," Immunological Reviews, vol. 234, no. 1, pp. 5-17, 2010.
46. M. Heusinkveld and S. H. van der Burg, "Identification and manipulation of tumor associated macrophages in human cancers," Journal of Translational Medicine, vol. 9, article 216, 2011.
47. P. J. Murray, J. E. Allen, S. K. Biswas et al., "Macrophage activation and polarization: nomenclature and experimental guidelines," Immunity, vol. 41, no. 1, pp. 14-20, 2014.
48. C. V. Jones and S. D. Ricardo, "Macrophages and CSF-1: implications for development and beyond," Organogenesis, vol. 9, no. 4, pp. 249-260, 2013.
49. A. Sica and A. Mantovani, "Macrophage plasticity and polarization: in vivo veritas," Journal of Clinical Investigation, vol. 122, no. 3, pp. 787-795, 2012.
50. S. Gordon and F. O. Martinez, "Alternative activation of macrophages: mechanism and functions," Immunity, vol. 32, no. 5, pp. 593-604, 2010.
51. E. Bonavita, M. R. Galdiero, S. Jaillon et al., "Phagocytes as corrupted policemen in cancer-related inflammation," Advances in Cancer Research, vol. 128, pp. 141-171, 2015.
52. E. Bonavita, S. Gentile, M. Rubino et al., "PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer," Cell, vol. 160, no. 4, pp. 700-714, 2015.
53. S. K. Biswas and A. Mantovani, "Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm," Nature Immunology, vol. 11, no. 10, pp. 889-896, 2010.
54. D. M. Mosser and J. P. Edwards, "Exploring the full spectrum of macrophage activation," Nature Reviews Immunology, vol. 8, no. 12, pp. 958-969, 2008.
55. M. Heusinkveld, P. J. de Vos van Steenwijk, R. Goedemans et al., "M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells," The Journal of Immunology, vol. 187, no. 3, pp. 1157-1165, 2011.
56. F. O. Martinez, L. Helming, and S. Gordon, "Alternative activation of macrophages: an immunologic functional perspective," Annual Review of Immunology, vol. 27, pp. 451-483, 2009.
57. D. Laoui, K. Movahedi, E. Van Overmeire et al., "Tumorassociated macrophages in breast cancer: distinct subsets, distinct functions," International Journal of Developmental Biology, vol. 55, no. 7-9, pp. 861-867, 2011.
58. F. O. Martinez, S. Gordon, M. Locati, and A. Mantovani, "Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression, "The Journal of Immunology, vol. 177, no. 10, pp. 7303-7311, 2006.
59. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, "Macrophage polarization: tumor-associated macrophages as a paradigmfor polarizedM2mononuclear phagocytes," Trends in Immunology, vol. 23, no. 11, pp. 549-555, 2002.
60. W. Yan, X. Liu, H. Ma et al., "Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages," Gut, vol. 64, no. 10, pp. 1593-1604, 2015.
61. V. Gocheva, H.-W. Wang, B. B. Gadea et al., "IL-4 induces cathepsin protease activity in tumor-associatedmacrophages to promote cancer growth and invasion," Genes and Development, vol. 24, no. 3, pp. 241-255, 2010.
62. Y. Nagakawa, T. Aoki, K. Kasuya, A. Tsuchida, and Y. Koyanagi, "Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer," Pancreas, vol. 24, no. 2, pp. 169-178, 2002.
63. R. Wang, J. Zhang, S. Chen et al., "Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression," Lung Cancer, vol. 74, no. 2, pp. 188-196, 2011.
64. S. Sousa, R. Brion, M. Lintunen et al., "Human breast cancer cells educate macrophages toward the M2 activation status," Breast Cancer Research, vol. 17, no. 1, article 101, 2015.
65. L. R. Bohrer and K. L. Schwertfeger, "Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner," Molecular Cancer Research, vol. 10, no. 10, pp. 1294-1305, 2012.
66. W. Fang, L. Ye, L. Shen et al., "Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8," Carcinogenesis, vol. 35, no. 8, pp. 1780-1787, 2014.
67. X.-Z. Ye, S.-L. Xu, Y.-H. Xin et al., "Tumor-associated microglia/ macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway, "TheJournal of Immunology, vol. 189, no. 1, pp. 444-453, 2012.
68. R. Singh, B. S. Shankar, and K. B. Sainis, "TGF-beta1-ROSATM- CREB signaling axis in macrophage mediated migration of human breast cancerMCF7 cells," Cellular Signalling, vol. 26, no. 7, pp. 1604-1615, 2014.
69. D. Li, X. Wang, J.-L. Wu et al., "Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro," PLoS ONE, vol. 8, no. 2, Article ID e56616, 2013.
70. B. Sainz Jr., S. Alcala, E. Garcia et al., "Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment," Gut, vol. 64, no. 12, pp. 1921-1935, 2015.
71. E. Y. Lin, J.-F. Li, L. Gnatovskiy et al., "Macrophages regulate the angiogenic switch in a mouse model of breast cancer," Cancer Research, vol. 66, no. 23, pp. 11238-11246, 2006.
72. C. Murdoch, M. Muthana, S. B. Coffelt, and C. E. Lewis, "The role of myeloid cells in the promotion of tumour angiogenesis," Nature Reviews Cancer, vol. 8, no. 8, pp. 618-631, 2008.
73. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation," Nature, vol. 454, no. 7203, pp. 436-444, 2008.
74. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, "Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy," European Journal of Cancer, vol. 42, no. 6, pp. 717-727, 2006.
75. M. R. Galdiero, E. Bonavita, I. Barajon, C. Garlanda, A. Mantovani, and S. Jaillon, "Tumor associated macrophages and neutrophils in cancer," Immunobiology, vol. 218, no. 11, pp. 1402-1410, 2013.
76. C. Raggi, H. S. Mousa, M. Correnti, A. Sica, and P. Invernizzi, "Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies," Oncogene, 2015.
77. M. R. Alison, S. Islam, and N. A. Wright, "Stem cells in cancer: instigators and propagators?" Journal of Cell Science, vol. 123, part 14, pp. 2357-2368, 2010.
78. H. Korkaya, S. Liu, and M. S. Wicha, "Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots," Clinical Cancer Research, vol. 17, no. 19, pp. 6125-6129, 2011.
79. E. M. Moran, "Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks," Journal of Environmental Pathology, Toxicology and Oncology, vol. 21, no. 2, pp. 193-201, 2002.
80. M. Karin and F. R. Greten, "NF-kappaB: linking inflammation and immunity to cancer development and progression," Nature Reviews Immunology, vol. 5, no. 10, pp. 749-759, 2005.
81. F. R. Greten, L. Eckmann, T. F. Greten et al., "IKKβ links inflammation and tumorigenesis in a mouse model of colitisassociated cancer," Cell, vol. 118, no. 3, pp. 285-296, 2004.
82. J. Bollrath, T. J. Phesse, V. A. von Burstin et al., "gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis," Cancer Cell, vol. 15, no. 2, pp. 91-102, 2009.
83. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability," Carcinogenesis, vol. 30, no. 7, pp. 1073-1081, 2009.
84. M. Kortylewski, H. Xin, M. Kujawski et al., "Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment," Cancer Cell, vol. 15, no. 2, pp. 114-123, 2009.
85. H. L. LaMarca, A. P. Visbal, C. J. Creighton et al., "CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland," STEM CELLS, vol. 28, no. 3, pp. 535-544, 2010.
86. S. Maeda, H. Kamata, J.-L. Luo, H. Leffert, and M. Karin, "IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis," Cell, vol. 121, no. 7, pp. 977-990, 2005.
87. D. Iliopoulos, H. A. Hirsch, and K. Struhl, "An epigenetic switch involving NF-κB, Lin28, Let-7MicroRNA, and IL6 links inflammation to celltransformation," Cell, vol. 139, no. 4, pp. 693-706, 2009.
88. S. Y. Song, M. Gannon, M. K. Washington et al., "Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha," Gastroenterology, vol. 117, no. 6, pp. 1416-1426, 1999.
89. G.-Y. Liou, H. Döppler, B. Necela et al., "Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs," The Journal of Cell Biology, vol. 202, no. 3, pp. 563-577, 2013.
90. C. Guerra, A. J. Schuhmacher, M. Cañamero et al., "Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice," Cancer Cell, vol. 11, no. 3, pp. 291-302, 2007.
91. G.-Y. Liou, H. Döppler, B. Necela et al., "MutantKRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions," Cancer Discovery, vol. 5, no. 1, pp. 52-63, 2015.
92. K. Miyamoto, K. Y. Araki, K. Naka et al., "Foxo3a is essential for maintenance of the hematopoietic stem cell pool," Cell Stem Cell, vol. 1, no. 1, pp. 101-112, 2007.
93. M. Diehn, R.W. Cho, N. A. Lobo et al., "Association of reactive oxygen species levels and radioresistance in cancer stem cells," Nature, vol. 458, no. 7239, pp. 780-783, 2009.
94. T. M. Phillips, W. H. McBride, and F. Pajonk, "The response of CD24 -/low/CD44 + breast cancer-initiating cells to radiation," Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777-1785, 2006.
95. F. Balkwill and A. Mantovani, "Inflammation and cancer: back to Virchow?" The Lancet, vol. 357, no. 9255, pp. 539-545, 2001.
96. S. P. Gao, K. G. Mark, K. Leslie et al., "Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas," Journal of Clinical Investigation, vol. 117, no. 12, pp. 3846-3856, 2007.
97. D. J. J. Waugh and C. Wilson, "The interleukin-8 pathway in cancer," Clinical Cancer Research, vol. 14, no. 21, pp. 6735-6741, 2008.
98. C. Ginestier, S. Liu, M. E. Diebel et al., "CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts," Journal of Clinical Investigation, vol. 120, no. 2, pp. 485-497, 2010.
99. P. J. Barnes and M. Karin, "Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases," TheNew England Journal ofMedicine, vol. 336, no. 15, pp. 1066-1071, 1997.
100. S. Wan, E. Zhao, I. Kryczek et al., "Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells," Gastroenterology, vol. 147, no. 6, pp. 1393-1404, 2014.
101. J. B. Mitchem, D. J. Brennan, B. L. Knolhoff et al., "Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses," Cancer Research, vol. 73, no. 3, pp. 1128-1141, 2013.
102. S. Le Gouvello, S. Bastuji-Garin, N. Aloulou et al., "High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas," Gut, vol. 57, no. 6, pp. 772-779, 2008.
103. Y. Miyahara, K. Odunsi, W. Chen, G. Peng, J. Matsuzaki, and R.-F. Wang, "Generation and regulation of human CD4+ IL-17- producing T cells in ovarian cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 40, pp. 15505-15510, 2008.
104. K. S. Sfanos, T. C. Bruno, C. H. Maris et al., "Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing," Clinical Cancer Research, vol. 14, no. 11, pp. 3254-3261, 2008.
105. X. Zhu, L. A. Mulcahy, R. A. A. Mohammed et al., "IL-17 expression by breast-cancer-associatedmacrophages: IL-17 promotes invasiveness of breast cancer cell lines," Breast Cancer Research, vol. 10, no. 6, article R95, 2008.
106. T. Xiang, H. Long, L. He et al., "Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer," Oncogene, vol. 34, no. 2, pp. 165-176, 2015.
107. R. Ward, A. H. Sims, A. Lee et al., "Monocytes andmacrophages, implications for breast cancer migration and stem cell-like activity and treatment," Oncotarget, vol. 6, no. 16, pp. 14687-14699, 2015.
108. S. Goswami, E. Sahai, J. B. Wyckoff et al., "Macrophages promote the invasion of breast carcinoma cells via a colonystimulating factor-1/epidermal growth factor paracrine loop," Cancer Research, vol. 65, no. 12, pp. 5278-5283, 2005.
109. J. Yang, D. Liao, C. Chen et al., "Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway," STEM CELLS, vol. 31, no. 2, pp. 248-258, 2013.
110. O. Leis, A. Eguiara, E. Lopez-Arribillaga et al., "Sox2 expression in breast tumours and activation in breast cancer stem cells," Oncogene, vol. 31, no. 11, pp. 1354-1365, 2012.
111. N. Tiwari, V. K. Tiwari, L. Waldmeier et al., "Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming," Cancer Cell, vol. 23, no. 6, pp. 768-783, 2013.
112. C.-J. Chang, J.-Y. Yang, W. Xia et al., "EZH2promotes expansion of breast tumor initiating cells through activation of RAF1-β- catenin signaling," Cancer Cell, vol. 19, no. 1, pp. 86-100, 2011.
113. H. Lu, K. R. Clauser, W. L. Tam et al., "A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages," Nature Cell Biology, vol. 16, no. 11, pp. 1105-1117, 2014.
114. M. Jinushi, M. Sato, A. Kanamoto et al., "Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms," The Journal of Experimental Medicine, vol. 206, no. 6, pp. 1317-1326, 2009.
115. W. Zhou, S. Q. Ke, Z. Huang et al., "Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth," Nature Cell Biology, vol. 17, no. 2, pp. 170-182, 2015.
116. B. Sainz Jr., B. Martín, M. Tatari, C. Heeschen, and S. Guerra, "ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells," Cancer Research, vol. 74, no. 24, pp. 7309-7320, 2014.
117. M.-J. Brissette, S. Lepage, A.-S. Lamonde et al., "MFGE8 released by apoptotic endothelial cells triggers antiinflammatory macrophage reprogramming," PLoS ONE, vol. 7, no. 4, Article ID e36368, 2012.
118. E.Y. Lin, A.V. Nguyen, R. G. Russell, and J.W. Pollard, "Colonystimulating factor 1 promotes progression of mammary tumors to malignancy, "The Journal of Experimental Medicine, vol. 193, no. 6, pp. 727-740, 2001.
119. P. Rodrigues, F. O. Hering, and A. Meller, "Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: a prospective study," Cancer Research and Treatment, vol. 43, no. 4, pp. 231-235, 2011.
120. W. Zhang, X.-D. Zhu, H.-C. Sun et al., "Depletion of tumorassociated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects," Clinical Cancer Research, vol. 16, no. 13, pp. 3420-3430, 2010.
121. I. Baccelli, A. Schneeweiss, S. Riethdorf et al., "Identification of a population of blood circulating tumor cells frombreast cancer patients that initiates metastasis in a xenograft assay," Nature Biotechnology, vol. 31, no. 6, pp. 539-544, 2013.
122. E. Zoni, G. van der Horst, A. F. van de Merbel et al., "miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α 6-integrin expression," Cancer Research, vol. 75, no. 11, pp. 2326-2336, 2015.
123. C. L. Hodgkinson, C. J. Morrow, Y. Li et al., "Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer," Nature Medicine, vol. 20, no. 8, pp. 897-903, 2014.
124. A. Cano, P. G. Santamaría, and G. Moreno-Bueno, "LOXL2 in epithelial cell plasticity and tumor progression," Future Oncology, vol. 8, no. 9, pp. 1095-1108, 2012.
125. N. Takebe, R. Q. Warren, and S. P. Ivy, "Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition," Breast Cancer Research, vol. 13, no. 3, p. 211, 2011.
126. Q.-M. Fan, Y.-Y. Jing, G.-F. Yu et al., "Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma," Cancer Letters, vol. 352, no. 2, pp. 160-168, 2014.
127. S. Su, Q. Liu, J. Chen et al., "A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis," Cancer Cell, vol. 25, no. 5, pp. 605-620, 2014.
128. C.-H. Lee, S.-Y. Liu, K.-C. Chou et al., "Tumor-associated macrophages promote oral cancer progression through activation of the Axl signaling pathway," Annals of Surgical Oncology, vol. 21, no. 3, pp. 1031-1037, 2014.
129. C.-Y. Liu, J.-Y. Xu, X.-Y. Shi et al., "M2-polarized tumorassociated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL- 10 signaling pathway," Laboratory Investigation, vol. 93, no. 7, pp. 844-854, 2013.
130. A.-K. Bonde, V. Tischler, S. Kumar, A. Soltermann, and R. A. Schwendener, "Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors," BMC Cancer, vol. 12, article 35, 2012.
131. C.-Y. Lin, C.-J. Lin, K.-H. Chen, J.-C. Wu, S.-H. Huang, and S.-M. Wang, "Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction," FEBS Letters, vol. 580, no. 13, pp. 3042-3050, 2006.
132. C. H. Zhang, F. L. Guo, G. L. Xu et al., "STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells," Hepatogastroenterology, vol. 61, no. 132, pp. 1082-1089, 2014.
133. N. Zhou, Y. Zhang, X. Zhang et al., "Exposure of tumorassociated macrophages to apoptotic MCF-7 cells promotes breast cancer growth and metastasis," International Journal of Molecular Sciences, vol. 16, no. 6, pp. 11966-11982, 2015.
134. M. Jinushi, S. Chiba, H. Yoshiyama et al., "Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 30, pp. 12425-12430, 2011.
135. S. A. Mani, W. Guo, M.-J. Liao et al., "The epithelialmesenchymal transition generates cells with properties of stem cells," Cell, vol. 133, no. 4, pp. 704-715, 2008.
136. S. B. Krantz, M. A. Shields, S. Dangi-Garimella, H. G. Munshi, and D. J. Bentrem, "Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression," Journal of Surgical Research, vol. 173, no. 1, pp. 105-112, 2012.
137. A. Dovas, A. Patsialou, A. S. Harney, J. Condeelis, and D. Cox, "Imaging interactions between macrophages and tumour cells that are involved in metastasis in vivo and in vitro," Journal of Microscopy, vol. 251, no. 3, pp. 261-269, 2013.
138. A. E. Powell, E. C. Anderson, P. S. Davies et al., "Fusion between intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming," Cancer Research, vol. 71, no. 4, pp. 1497-1505, 2011.
139. T. Tsubouchi, J. Soza-Ried, K. Brown et al., "DNA synthesis is required for reprogrammingmediated by stemcell fusion," Cell, vol. 152, no. 4, pp. 873-883, 2013.
140. H.M. Schramm, "Should EMT of cancer cells be understood as epithelial-myeloid transition?" Journal of Cancer, vol. 5, no. 2, pp. 125-132, 2014.
141. J. M. Pawelek and A. K. Chakraborty, "Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis," Nature Reviews Cancer, vol. 8, no. 5, pp. 377-386, 2008.
142. J. M. Pawelek and A. K. Chakraborty, "The cancer cell- leukocyte fusion theory of metastasis," in Advances in Cancer Research, vol. 101, chapter 10, pp. 397-444, Academic Press, New York, NY, USA, 2008.
143. G. A. Clawson, G. L. Matters, P. Xin et al., "Macrophage-tumor cell fusions from peripheral blood of melanoma patients," PLoS ONE, vol. 10, no. 8, Article IDe0134320, 2015.
144. R. Lazova, G. S. LaBerge, E. Duvall et al., "A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer," PLoS ONE, vol. 8, no. 6, Article ID e66731, 2013.
145. D. L. Adams, S. S. Martin, R. K. Alpaugh et al., "Circulating giant macrophages as a potential biomarker of solid tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 9, pp. 3514-3519, 2014.
146. K. J. Luzzi, I. C. MacDonald, E. E. Schmidt et al., "Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases," The American Journal of Pathology, vol. 153, no. 3, pp. 865-873, 1998.
147. C.W. Wong, A. Lee, L. Shientag et al., "Apoptosis: an early event in metastatic inefficiency," Cancer Research, vol. 61, no. 1, pp. 333-338, 2001.
148. T. Oskarsson, E. Batlle, and J. Massagué, "Metastatic stem cells: sources, niches, and vital pathways," Cell Stem Cell, vol. 14, no. 3, pp. 306-321, 2014.
149. S. Liu, Y. Cong, D. Wang et al., "Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts," StemCell Reports, vol. 2, no. 1, pp. 78-91, 2014.
150. M. Balic, H. Lin, L. Young et al., "Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype," Clinical Cancer Research, vol. 12, no. 19, pp. 5615-5621, 2006.
151. V. Plaks, C.D. Koopman, and Z. Werb, "Circulating tumor cells," Science, vol. 341, no. 6151, pp. 1186-1188, 2013.
152. B. Qian, Y. Deng, J. H. Im et al., "A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth," PLoS ONE, vol. 4, no. 8, Article ID e6562, 2009.
153. R. N. Kaplan, R. D. Riba, S. Zacharoulis et al., "VEGFR1- positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche," Nature, vol. 438, no. 7069, pp. 820-827, 2005.
154. H. W. van Deventer, D. A. Palmieri, Q. P. Wu, E. C. McCook, and J. S. Serody, "Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2," The Journal of Immunology, vol. 190, no. 9, pp. 4861-4867, 2013.
155. A. M. Gil-Bernabé, Š. Ferjančič, M. Tlalka et al., "Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice," Blood, vol. 119, no. 13, pp. 3164-3175, 2012.
156. B. Costa-Silva, N. M. Aiello, A. J. Ocean et al., "Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver," Nature Cell Biology, vol. 17, no. 6, pp. 816-826, 2015.
157. T. Kitamura, B.-Z. Qian, and J. W. Pollard, "Immune cell promotion of metastasis," Nature Reviews Immunology, vol. 15, no. 2, pp. 73-86, 2015.
158. G. Germano, R. Frapolli, C. Belgiovine et al., "Role of macrophage targeting in the antitumor activity of trabectedin," Cancer Cell, vol. 23, no. 2, pp. 249-262, 2013.
159. C. H. Ries, M. A. Cannarile, S. Hoves et al., "Targeting tumorassociated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy," Cancer Cell, vol. 25, no. 6, pp.846-859, 2014.
160. F. Hussain, M. Freissmuth, D. Völkel et al., "Human antimacrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivo," Molecular Cancer Therapeutics, vol. 12, no. 7, pp. 1223-1234, 2013.
161. T. Yamashina, M. Baghdadi, A. Yoneda et al., "Cancer stemlike cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells," Cancer Research, vol. 74, no. 10, pp. 2698-2709, 2014.
162. M. Cioffi, S. Trabulo, M. Hidalgo et al., "Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms," Clinical Cancer Research, vol. 21, no. 10, pp. 2325-2337, 2015.
163. T. K.-W. Lee, V. C.-H. Cheung, P. Lu et al., "Blockade of CD47- mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma," Hepatology, vol. 60, no. 1, pp. 179-191, 2014.
164. T. Matozaki, Y. Murata, H. Okazawa, and H. Ohnishi, "Functions and molecularmechanisms of the CD47-SIRPα signalling pathway," Trends in Cell Biology, vol. 19, no. 2, pp. 72-80, 2009.
165. K. S. Chan, I. Espinosa, M. Chao et al., "Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14016-14021, 2009.
166. R. Majeti, M. P. Chao, A. A. Alizadeh et al., "CD47 is an adverse prognostic factor and therapeutic antibody target on human acutemyeloid leukemia stem cells," Cell, vol. 138, no. 2, pp. 286-299, 2009.